<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Galderma, de medische tak van Nestlé Skin Health, kondigt positieve resultaten aan van fase 2b-studie van Nemolizumab bij patiënten met matig tot zeer matig atopische dermatitis	</title>
	<atom:link href="https://www.novumpr.nl/2018/10/31/galderma-de-medische-tak-van-nestle-skin-health-kondigt-positieve-resultaten-aan-van-fase-2b-studie-van-nemolizumab-bij-patienten-met-matig-tot-zeer-matig-atopische-dermatitis/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2018/10/31/galderma-de-medische-tak-van-nestle-skin-health-kondigt-positieve-resultaten-aan-van-fase-2b-studie-van-nemolizumab-bij-patienten-met-matig-tot-zeer-matig-atopische-dermatitis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=galderma-de-medische-tak-van-nestle-skin-health-kondigt-positieve-resultaten-aan-van-fase-2b-studie-van-nemolizumab-bij-patienten-met-matig-tot-zeer-matig-atopische-dermatitis</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Wed, 31 Oct 2018 10:15:44 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.3</generator>
</channel>
</rss>
